David Sarraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Sarraf has a total of 655 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Feo
Retina Division, Stein Eye Institute, University of California of Los Angeles, David Geffen School of Medicine at UCLA, Los Angeles, CA; Humanitas University, Milan, Italy
22 shared publicationsSriniVas Sadda
Doheny Eye Institute, University of California, Los Angeles, Pasadena, California, USA
21 shared publications- Kenneth Bailey Freund
Vitreous Retina Macula Consultants of New York, New York, New York
20 shared publications Elodie Bousquet
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California
16 shared publicationsSriniVas R. Sadda
15 shared publicationsAhmad Santina
Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California
13 shared publications
Latest Publications
- 12 October 2026
- Published by Wolters Kluwer Health in Retina
LAMELLAR MACULAR HOLE AFTER ACQUIRED VITELLIFORM LESION COLLAPSE IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
Was not provided for this article.
- 12 October 2026
- Published by Wolters Kluwer Health in Retina
LAMELLAR MACULAR HOLE AFTER ACQUIRED VITELLIFORM LESION COLLAPSE IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION
Was not provided for this article.
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
Loss to Follow-Up and Subway Proximity in Proliferative Diabetic Retinopathy and Diabetic Macular Edema: CLEAR Study Report 2
Purpose: To investigate the association between home subway proximity and being lost to follow-up (LTFU) in patients with proliferative diabetic retinopathy (PDR) or diabetic macular edema (DME). Methods: This multi-center, retrospective cohort study included patients from the Greater Toronto Area with available residential address data who were treated with either intravitreal anti-vascular endothelial growth factor therapy or panretinal photocoagulation for PDR or DME between January 1 st , 2012, and December 31 st , 2021. LTFU was defined as the absence of an ophthalmic visit within one year of their most recent visit. Univariable and multivariable logistic regression models assessed associations between these transportation variables and LTFU status. Results: Among 2,755 patients with PDR or DME (mean age: 71 ± 13 years) who had available residential address data, 477 (17%) were LTFU over a mean follow-up period of 59 ± 19 months. In the multivariable analysis adjusting for total distance to the point of care and relevant confounding variables, patients residing farther from a subway station were more likely to be LTFU (>10 km: OR=2.04, 95%CI=[1.44-2.91], p10 stops: OR=1.51, 95%CI=[1.10-2.39], p=0.015) and line transfers (1 transfer: OR=1.63, 95%CI=[1.29-2.05], p60 minutes: OR=2.07, 95%CI=[1.86-2.95], p<0.001). Conclusion: Limited subway proximity was associated with an increased odds of being LTFU, highlighting the importance of addressing transportation barriers and improving the accessibility of ophthalmic care in areas with limited public transit infrastructure to improve follow-up adherence.
- 21 September 2026
- Published by Wolters Kluwer Health in Retina
Loss to Follow-Up and Subway Proximity in Proliferative Diabetic Retinopathy and Diabetic Macular Edema: CLEAR Study Report 2
Purpose: To investigate the association between home subway proximity and being lost to follow-up (LTFU) in patients with proliferative diabetic retinopathy (PDR) or diabetic macular edema (DME). Methods: This multi-center, retrospective cohort study included patients from the Greater Toronto Area with available residential address data who were treated with either intravitreal anti-vascular endothelial growth factor therapy or panretinal photocoagulation for PDR or DME between January 1 st , 2012, and December 31 st , 2021. LTFU was defined as the absence of an ophthalmic visit within one year of their most recent visit. Univariable and multivariable logistic regression models assessed associations between these transportation variables and LTFU status. Results: Among 2,755 patients with PDR or DME (mean age: 71 ± 13 years) who had available residential address data, 477 (17%) were LTFU over a mean follow-up period of 59 ± 19 months. In the multivariable analysis adjusting for total distance to the point of care and relevant confounding variables, patients residing farther from a subway station were more likely to be LTFU (>10 km: OR=2.04, 95%CI=[1.44-2.91], p10 stops: OR=1.51, 95%CI=[1.10-2.39], p=0.015) and line transfers (1 transfer: OR=1.63, 95%CI=[1.29-2.05], p60 minutes: OR=2.07, 95%CI=[1.86-2.95], p<0.001). Conclusion: Limited subway proximity was associated with an increased odds of being LTFU, highlighting the importance of addressing transportation barriers and improving the accessibility of ophthalmic care in areas with limited public transit infrastructure to improve follow-up adherence.
- 11 September 2026
- Published by Elsevier in Ophthalmology Retina
Type 1 Nonexudative Macular Neovascularization: 10-Year Follow-Up with En Face OCT
- 11 September 2026
- Published by Elsevier in Ophthalmology Retina
Type 1 Nonexudative Macular Neovascularization: 10-Year Follow-Up with En Face OCT
- Open Access
- 3 September 2026
- Published by Elsevier in Ophthalmology Retina
Evidence and Consensus-Based Imaging Guidelines in Ocular Toxoplasmosis Multimodal Imaging in Uveitis Task Force Report 14
- 3 September 2026
- Published by Elsevier in Ophthalmology Retina
Open AccessEvidence and Consensus-Based Imaging Guidelines in Ocular Toxoplasmosis Multimodal Imaging in Uveitis Task Force Report 14
- Open Access
- 25 August 2026
- Published by Elsevier in Ophthalmology Retina
Evidence and Consensus Based Imaging Guidelines in Behçet Disease Uveitis. Multimodal Imaging in Uveitis (MUV) Taskforce Report 18
- 25 August 2026
- Published by Elsevier in Ophthalmology Retina
Open AccessEvidence and Consensus Based Imaging Guidelines in Behçet Disease Uveitis. Multimodal Imaging in Uveitis (MUV) Taskforce Report 18
- 29 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 292-300
Internal Limiting Membrane Loop Configurations in Epiretinal Membrane: Prevalence, Imaging Associations and Optical Coherence Tomography Morphology
- 29 July 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 292-300
Internal Limiting Membrane Loop Configurations in Epiretinal Membrane: Prevalence, Imaging Associations and Optical Coherence Tomography Morphology
- Open Access
- 21 July 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-3
Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2
Purpose: To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel). Methods: This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham, n = 98; treated, n = 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression. Results: In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss ( P = 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users ( P = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status ( P = 0.577). Secondary functional metrics showed no significant differences between groups across either cohort. Conclusions: AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.
- 21 July 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-3
Open AccessAssociation between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2
Purpose: To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel). Methods: This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham, n = 98; treated, n = 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression. Results: In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss ( P = 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users ( P = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status ( P = 0.577). Secondary functional metrics showed no significant differences between groups across either cohort. Conclusions: AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.
- Open Access
- 29 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (11) , e135-e149
Evidence and Consensus-Based Imaging Guidelines in Tubercular Choroiditis
- 29 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (11) , e135-e149
Open AccessEvidence and Consensus-Based Imaging Guidelines in Tubercular Choroiditis